Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kensey Nash touts TriActiv FX results

This article was originally published in The Gray Sheet

Executive Summary

The 3.2% major adverse cardiac event (MACE) rate seen in the firm's prospective ASPIRE registry "is the lowest recorded to date from a sizable multi-center study of the [saphenous vein graft] population, and is less than half of the next best data set widely quoted by the cardiology community," the company said March 7. The results also demonstrate a 2.2% incidence of heart attacks with the TriActiv FX embolic protection system. Kensey Nash will showcase the registry data at the American College of Cardiology meeting in Atlanta this week (1"The Gray Sheet" Feb. 6, 2006, p. 10)...
Advertisement

Related Content

Kensey Nash’s next-gen TriActiv
Kensey Nash Looks To Augment TriActiv Embolic Protection Offerings
Kensey Nash Looks To Augment TriActiv Embolic Protection Offerings
Advertisement
UsernamePublicRestriction

Register

MT023315

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel